Lung cancer<unk>  caused tumors to shrink or stabilize in 90% of 82 patients carrying the ALK fusion gene. Tumors shrank at least 30% in 57% of people treated. Most had adenocarcinoma, and had never smoked or were former smokers. They had undergone treatment with an average of three other drugs prior to receiving<unk> , and only 10% were expected to respond to standard therapy. They were given 250 mg<unk>  twice daily for a median duration of six months. Approximately 50% of these patients suffered at least one side effect, such as nausea, vomiting, or diarrhea. Some responses to<unk>  have lasted up to 15 months. A Phase III trial, PROFILE 1007, compares<unk>  to standard second line chemotherapy (pemetrexed or taxotere) in the treatment of ALK-positive NSCLC. Additionally, a phase 2 trial, PROFILE 1005, studies patients meeting similar criteria who have received more than one line of prior chemotherapy. In February 2016, the J-ALEX phase III study comparing alectinib with<unk>  ALK-positive metastatic NSCLC was terminated early because an interim analysis showed that progression-free survival was longer with alectinib. These results were confirmed in a 2017 analysis. Lymphomas In people affected by relapsed or refractory ALK+ anaplastic large cell lymphoma,<unk>  produced objective response rates ranging from 65% to 90% and 3 year progression free survival rates of 60-75%. No relapse of the lymphoma was ever observed after the initial 100 days of treatment. Treatment must be continued indefinitely at present. Other cancers<unk>  is also being tested in clinical trials of advanced disseminated neuroblastoma.
Crizotinib
Icotinib
Nilotinib
Tepotinib
Afatinib
Imatinib
Ruxolitinib
Neratinib